DURECT Corporation

NasdaqCM:DRRX Voorraadrapport

Marktkapitalisatie: US$41.6m

DURECT Balans Gezondheid

Financiële gezondheid criteriumcontroles 2/6

DURECT has a total shareholder equity of $5.0M and total debt of $12.5M, which brings its debt-to-equity ratio to 249.1%. Its total assets and total liabilities are $29.9M and $24.8M respectively.

Belangrijke informatie

249.1%

Verhouding schuld/eigen vermogen

US$12.55m

Schuld

Rente dekkingsration/a
ContantUS$15.65m
AandelenUS$5.04m
Totaal verplichtingenUS$24.82m
Totaal activaUS$29.85m

Recente financiële gezondheidsupdates

Is DURECT (NASDAQ:DRRX) A Risky Investment?

May 12
Is DURECT (NASDAQ:DRRX) A Risky Investment?

Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?

Jan 08
Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?

Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?

Aug 05
Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?

Recent updates

Brokers Are Upgrading Their Views On DURECT Corporation (NASDAQ:DRRX) With These New Forecasts

Aug 08
Brokers Are Upgrading Their Views On DURECT Corporation (NASDAQ:DRRX) With These New Forecasts

Durect names ex-RBC Capital Markets executive as CFO

Jul 05

Is DURECT (NASDAQ:DRRX) A Risky Investment?

May 12
Is DURECT (NASDAQ:DRRX) A Risky Investment?

DURECT Corporation (NASDAQ:DRRX) Analysts Are More Bearish Than They Used To Be

Mar 14
DURECT Corporation (NASDAQ:DRRX) Analysts Are More Bearish Than They Used To Be

DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 10
DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?

Jan 08
Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?

Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?

Aug 05
Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?

Durect (DRRX) Investor Presentation - Slideshow

May 06

Durect EPS misses by $0.01, misses on revenue

May 04

DURECT prices ~$43M stock offering

Feb 04

DURECT surges after FDA approval for Posimir

Feb 02

Durect's DUR-928 fast track'd for alcoholic hepatitis in the U.S.

Dec 16

DURECT (DRRX) Investor Presentation - Slideshow

Oct 31

Analyse van de financiële positie

Kortlopende schulden: DRRX's short term assets ($20.0M) do not cover its short term liabilities ($21.9M).

Langlopende schulden: DRRX's short term assets ($20.0M) exceed its long term liabilities ($2.9M).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: DRRX has more cash than its total debt.

Schuld verminderen: DRRX's debt to equity ratio has increased from 90.9% to 249.1% over the past 5 years.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: DRRX has less than a year of cash runway based on its current free cash flow.

Voorspelling contante baan: DRRX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 16.6% each year


Ontdek gezonde bedrijven